

AMENDMENTS TO THE CLAIMS

1-18. **(Canceled)**

19. **(Previously Presented)** An antibody, or epitope-binding fragment thereof, which has the characteristics of a monoclonal antibody selected from the group consisting of 6E10, 13H8, and 6D8 produced by hybridomas with ATCC accession numbers CRL 10514, CRL 10510, and CRL 10513, respectively.

20. **(Previously Presented)** A monoclonal antibody, selected from the group consisting of monoclonal antibodies 5B3, 5B6, 5C2, 6D8, 6E10, 7F11, 7G11, 9E3, 10C1, 13H8, 14F12, AND 15G7, which is covalently bound to a detectable marker or a water insoluble matrix.

21. **(Currently Amended)** A composition suitable for administration to a patient, said composition comprising [consisting of] a monoclonal antibody selected from the group consisting of monoclonal antibodies 5B3, 5B6, 5C2, 6D8, 6E10, 7F11, 7G11, 9E3, 10C1, 13H8, 14F12, AND 15G7, in a sterile pharmaceutically acceptable vehicle.

22. **(Original)** The composition of claim 21, wherein said monoclonal antibody is conjugated to a toxin.

23. **(Original)** A method comprising administering a therapeutically acceptable dose of the composition of claim 21 to a patient having or at risk of having HIV infection.

24. **(Canceled)**

25. **(Canceled)**

26. **(Previously Presented)** The antibody or epitope-binding fragment thereof of claim 19 that is monoclonal.

27. **(Currently Amended)** The antibody or epitope-binding fragment thereof of claim 19 that is covalently bound to a detectable marker or a water insoluble matrix.

28. **(Previously Presented)** The antibody or epitope-binding fragment thereof of claim 26, selected from the group consisting of monoclonal antibodies 6E10, 13H8, and 6D8.

29. **(Previously Presented)** A hybridoma or cell culture comprising an antibody, or epitope-binding fragment thereof, which has the characteristics of a monoclonal antibody selected from the group consisting of 6E10, 13H8, and 6D8 produced by hybridomas with ATCC accession numbers CRL 10514, CRL 10510, and CRL 10513, respectively.

30. **(Currently Amended)** A hybridoma of claim 29 selected from the group consisting of hybridomas with [hybridoma of] ATCC accession numbers CRL 10514, CRL 10510, and CRL 10513.